With the shortage resolved, the FDA is now phasing out this allowance, signaling a shift back to reliance on FDA-approved medicines
Clinical trials show that meaningful percentage weight loss often develops over several months, especially when medication is paired with diet and activity changes
Adverse Reactions in Clinical Trials in Adults with Obesity or Overweight WEGOVY 2.4 mg Subcutaneous Weekly Dosage WEGOVY was evaluated for safety in 3 randomized, double-blind, placebo-controlled trials that included 2,116 adult patients with obesity or overweight treated with 2.4 mg WEGOVY for up to 68 weeks and a 7 week off-drug follow-up period [see Clinical Studies (14.2)]
The third approved zone is the outer back of the upper arm, also known as the tricep region
These are FDA-approved finished drug products manufactured by Novo Nordisk and Eli Lilly respectively - products that went through the FDA's full pre-market approval process for safety, effectiveness, and quality
